Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Bunka

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Clinical Psychiatry|June 20, 2020
The Risk of Relapse of Depression During Pregnancy After Discontinuation of Antidepressants: A Systematic Review and Meta-AnalysisHamideh Bayrampour, Arunima Kapoor, Mary Bunka, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 4, 2024
Regarding the meta-analyses of pharmacogenomics-guided antidepressant treatment: A response to Milosavljevic et alMary Bunka, Jehannine Austin, Louisa Edwards, et al.
Pharmacogenomics|October 14, 2025
Characterizing models for delivery of pharmacogenomic testing: a scoping reviewZeina Waheed, Mary Bunka, Louisa Edwards, et al.
Pharmacoeconomics|July 25, 2022
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived ExperienceMary Bunka, Shahzad Ghanbarian, Linda Riches, et al.
Psychiatry Research|February 13, 2023
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysisMary Bunka, Gavin Wong, Dan Kim, et al.
Journal of Affective Disorders|May 7, 2026
Pharmacogenomic testing for major depressive disorder in British Columbia, Canada: Recommendations from a public deliberationLouisa Edwards, Colene Bentley, Kieran C O'Doherty, et al.
BMC Health Services Research|December 21, 2023
Costs of major depression covered / not covered in British Columbia, CanadaSonya Cressman, Shahzad Ghanbarian, Louisa Edwards, et al.
BMJ Open|January 14, 2025
Relationship between pharmacotherapy for major depressive disorder and healthcare utilisation in British Columbia, Canada: a retrospective population-based cohortRohit Vijh, Zeina Waheed, Sandra Peterson, et al.
Pharmacoeconomics - Open|March 26, 2024
A Canadian Simulation Model for Major Depressive Disorder: Study ProtocolShahzad Ghanbarian, Gavin W K Wong, Mary Bunka, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|November 14, 2023
Cost-effectiveness of pharmacogenomic-guided treatment for major depressionShahzad Ghanbarian, Gavin W K Wong, Mary Bunka, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Psychiatry|June 20, 2020
The Risk of Relapse of Depression During Pregnancy After Discontinuation of Antidepressants: A Systematic Review and Meta-AnalysisHamideh Bayrampour, Arunima Kapoor, Mary Bunka, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 4, 2024
Regarding the meta-analyses of pharmacogenomics-guided antidepressant treatment: A response to Milosavljevic et alMary Bunka, Jehannine Austin, Louisa Edwards, et al.
Pharmacogenomics|October 14, 2025
Characterizing models for delivery of pharmacogenomic testing: a scoping reviewZeina Waheed, Mary Bunka, Louisa Edwards, et al.
Pharmacoeconomics|July 25, 2022
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived ExperienceMary Bunka, Shahzad Ghanbarian, Linda Riches, et al.
Psychiatry Research|February 13, 2023
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysisMary Bunka, Gavin Wong, Dan Kim, et al.
Journal of Affective Disorders|May 7, 2026
Pharmacogenomic testing for major depressive disorder in British Columbia, Canada: Recommendations from a public deliberationLouisa Edwards, Colene Bentley, Kieran C O'Doherty, et al.
BMC Health Services Research|December 21, 2023
Costs of major depression covered / not covered in British Columbia, CanadaSonya Cressman, Shahzad Ghanbarian, Louisa Edwards, et al.
BMJ Open|January 14, 2025
Relationship between pharmacotherapy for major depressive disorder and healthcare utilisation in British Columbia, Canada: a retrospective population-based cohortRohit Vijh, Zeina Waheed, Sandra Peterson, et al.
Pharmacoeconomics - Open|March 26, 2024
A Canadian Simulation Model for Major Depressive Disorder: Study ProtocolShahzad Ghanbarian, Gavin W K Wong, Mary Bunka, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|November 14, 2023
Cost-effectiveness of pharmacogenomic-guided treatment for major depressionShahzad Ghanbarian, Gavin W K Wong, Mary Bunka, et al.
Pageof 1